A retrospective study : Apolipoprotein B displays superior predictive value than other lipids for long-term prognosis in coronary atherosclerosis patients and particular subpopulations

Published: 31 May 2022| Version 1 | DOI: 10.17632/4g6frzr4gs.1


We revealed that apoB could be “risk-enhancing factor” in the patients with coronary atherosclerosis disease, while in the Normal population, LDL-C still acts as a major risk factor for predicting MACEs events. ApoB is a good predictor for long-term cardiovascular events in coronary atherosclerosis disease including AS group and CHD subpopulations (including CHD+DM, CHD+BMI≥25 and CHD+MS). ApoB is superior to other lipids in predicting the presence of myocardial infarction, hospitalization due to angina, cardiac death, particularly in CHD patients who complicated with diabetes, obesity and metabolic syndrome. Despite achieving optimal LDL-C or non-HDL-C level, CHD patients are still at risk of worse survival if they didn’t reach the tighter apoB control level (lower cut points like 65mg/dL). More attention should be paid to special populations with residual elevations of atherogenic particle numbers, and focusing on lowering base-line apoB helps achieving more long-term benefits.



Lipid, Diabetes, Obesity, Cardiovascular Disease, Metabolic Syndrome, Apolipoprotein B